Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kina vs TrueMe

Kina
Graded #107

Higher grade

vs+2.5
TrueMe
Graded #163

Lower grade

The verdict

Kina takes it — 70.1/100 to 67.6/100.

Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrueMe +1
61
62
Dose & formulationTrueMe +13
64
77
Clinical oversightKina +10
88
78
Labs & monitoringKina +12
64
52
FulfillmentKina +2
83
81
Contract termsKina +16
61
45
Kina · left barTrueMe · right bar

The numbers

MetricKinaTrueMe
WeighScore70.1/10067.6/100
GradeCC
Scorecard rank#107#163
Semaglutide$179/mo (starting dose, plus a separate fee, compounded)$159/mo (compounded)
Tirzepatide$179/mo (starting dose, compounded)$189/mo (compounded)
CoverageCoverage not published6 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Kina

Graded #107 · C

Strengths

  • Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
  • Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
  • Verifiable LegitScript certification (seal ID 50917967)
  • GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
  • Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Built for women navigating menopause — less tailored if that is not your situation
  • A separate $50 physician consultation fee applies on top of the medication price
  • The compounding pharmacy partner is not named, and the full list of served states is not published
TrueMe

Graded #163 · C

Strengths

  • One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
  • Same price at every dose, so the cost does not climb as a provider titrates the dose upward
  • Full pricing is published up front — no intake form is required before you can see what you will pay
  • Carries a genuine LegitScript-issued seal (ID 50205625) that resolves on LegitScript's own asset host
  • Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas

Where it loses points

  • Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
  • Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
  • You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
  • The 3-month rates ($119 and $139/mo) are a single upfront charge of $357 or $417, not a lower monthly plan
  • A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard